Feasibility of using thrombin generation assay (TGA) for monitoring of haemostasis during supplementation therapy in haemophilic patients without inhibitors

被引：18

作者：

Ay, Y. ^{[1
]}

Balkan, C. ^{[1
]}

Karapinar, D. Y. ^{[1
]}

Akin, M. ^{[1
]}

Bilenoglu, B. ^{[1
]}

Kavakli, K. ^{[1
]}

机构：

[1] Ege Univ, Dept Hematol, Childrens Hosp, Ege Hemophilia Ctr,Med Sch, TR-35100 Izmir, Turkey

来源：

HAEMOPHILIA | 2012年 / 18卷 / 06期

关键词：

haemophilia; thrombin generation assay; thromboelastography;

D O I：

10.1111/j.1365-2516.2012.02849.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Monitoring factor replacement treatment and observing concordance with clinical haemostasis is crucial in vital haemorrhages and major surgeries in haemophilic patients. We aimed to investigate the value of the thrombin generation assay (TGA) and thromboelastography (TEG) for monitoring haemostasis in haemophilic patients during factor replacement treatment. The study group consisted of 29 patients (21 haemophilia A, 8 haemophilia B). All the patients FVIII-inhibitor were negative. A total of 35 bleeding episodes and/or surgical interventions were evaluated. aPTT, FVIII/FIX activity, TEG and TGA tests were conducted before and after factor therapy during the bleeding episode or surgical prophylaxis of haemophilic patients. Correlations among these tests were evaluated and compared with clinical responses. No correlation was found among aPTT, factor activities and clinical outcome. There were also no correlation found between TEG parameters and clinical outcome. The only significant correlation found between TGA parameters and clinical outcome was the correlation between peak thrombin. In conclusion, we found superiority of TGA-peak thrombin over other traditional tests for monitoring haemostasis in haemophilic patients in this study.

引用

页码：911 / 916

页数：6

共 29 条

[1]

Varadi K., Turecek P.L., Schwarz P., Thrombin generation assay and other universal tests for monitoring hemophilia therapy, Haemophilia, 10, SUPPL. 2, pp. 17-21, (2004)

[2]

Van Veen J.J., Gatt A., Makris M., Thrombin generation testing in routine clinical practice: are we there yet?, Br J Haematol, 142, pp. 889-903, (2008)

[3]

Salvagno G.L., Berntrop E., Thrombin generation testing for monitoring hemophilia treatment: a clinical perspective, Seminars in Thrombosis and Hemostasis, pp. 780-90, (2010)

[4]

Shima M., Matsumoto T., Ogiwara K., New assays for monitoring haemophilia treatment, Haemophilia, 14, 3, pp. 83-92, (2008)

[5]

Sorensen B., Ingerslev J., Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thromboelastography, Haemophilia, 11, 1, pp. 1-6, (2005)

[6]

Dargaud Y., Beguin S., Lienhart A., Et al., Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B, Thromb Haemost, 93, pp. 475-80, (2005)

[7]

Varadi K., Turecek P.L., Schwarz P., Thrombin generation assay and other universal tests for monitoring hemophilia therapy, Haemophilia, SUPPL. 2, pp. 17-21, (2004)

[8]

Hemker H.C., Giesen P., Al Dieri R., Et al., Calibrated automated thrombin generation meausurement in clotting plasma, Pathophysiol Haemost Thromb, pp. 4-15, (2003)

[9]

Siegemund T., Petros S., Siegemund A., Et al., Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma, Thromb Haemost, 90, pp. 781-6, (2003)

[10]

Beltran-Miranda C.P., Khan A., Jaloma-Cruz A.R., Laffan M.A., Thrombin generation and phenotypic correlation in haemophilia A, Haemophilia, 11, pp. 326-34, (2005)

← 1 2 3 →